 | • レポートコード：MRC2-11QY11633 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は糖尿病性腎症のグローバル市場について調査・分析したレポートです。種類別（ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害薬、結合組織成長因子（CTGF）阻害薬、抗酸化炎症調節薬（AIM）、単球化学誘引物質タンパク質（MCP）阻害薬、エンドセリンA受容体（ETAR）拮抗薬Gタンパク質共役型受容体（GPCR））市場規模、用途別（病院、がん研究所、診断研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別糖尿病性腎症の競争状況、市場シェア ・世界の糖尿病性腎症市場：種類別市場規模 2015年-2020年（ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害薬、結合組織成長因子（CTGF）阻害薬、抗酸化炎症調節薬（AIM）、単球化学誘引物質タンパク質（MCP）阻害薬、エンドセリンA受容体（ETAR）拮抗薬Gタンパク質共役型受容体（GPCR）） ・世界の糖尿病性腎症市場：種類別市場規模予測 2021年-2026年（ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害薬、結合組織成長因子（CTGF）阻害薬、抗酸化炎症調節薬（AIM）、単球化学誘引物質タンパク質（MCP）阻害薬、エンドセリンA受容体（ETAR）拮抗薬Gタンパク質共役型受容体（GPCR）） ・世界の糖尿病性腎症市場：用途別市場規模 2015年-2020年（病院、がん研究所、診断研究所） ・世界の糖尿病性腎症市場：用途別市場規模予測 2021年-2026年（病院、がん研究所、診断研究所） ・北米の糖尿病性腎症市場分析：米国、カナダ ・ヨーロッパの糖尿病性腎症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの糖尿病性腎症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の糖尿病性腎症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの糖尿病性腎症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.
Market Analysis and Insights: Global Diabetic Nephropathy Market
The global Diabetic Nephropathy market size is projected to reach US$ 2522.4 million by 2026, from US$ 2398.5 million in 2020, at a CAGR of 4.8%% during 2021-2026.
Global Diabetic Nephropathy Scope and Market Size
Diabetic Nephropathy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Nephropathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma
Market segment by Type, the product can be split into
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Market segment by Application, split into
Hospitals
Cancer Research Institutes
Diagnostic Labs
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
1.4 Market by Type
1.4.1 Global Diabetic Nephropathy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ACE Inhibitors
1.4.3 ARBs
1.4.4 Diuretics
1.4.5 Calcium Channel Blockers(CCBs)
1.4.6 Renin Inhibitors
1.4.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.4.8 Antioxidant Inflammation Modulators(AIMs)
1.4.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.4.10 Endothelin-A Receptor(ETAR)Antagonist
1.4.11 G Protein-Coupled Receptors (GPCRs)
1.5 Market by Application
1.5.1 Global Diabetic Nephropathy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Diagnostic Labs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Nephropathy Market Perspective (2015-2026)
2.2 Global Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Nephropathy Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Nephropathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Diabetic Nephropathy Market Growth Strategy
2.3.6 Primary Interviews with Key Diabetic Nephropathy Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Market Size
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2015-2020)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Players (2015-2020)
3.1.3 Global Diabetic Nephropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Diabetic Nephropathy Market Concentration Ratio
3.2.1 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2019
3.3 Diabetic Nephropathy Key Players Head office and Area Served
3.4 Key Players Diabetic Nephropathy Product Solution and Service
3.5 Date of Enter into Diabetic Nephropathy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Diabetic Nephropathy Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Nephropathy Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Diabetic Nephropathy Market Size by Application (2015-2020)
5.2 Global Diabetic Nephropathy Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Diabetic Nephropathy Market Size (2015-2020)
6.2 Diabetic Nephropathy Key Players in North America (2019-2020)
6.3 North America Diabetic Nephropathy Market Size by Type (2015-2020)
6.4 North America Diabetic Nephropathy Market Size by Application (2015-2020)
7 Europe
7.1 Europe Diabetic Nephropathy Market Size (2015-2020)
7.2 Diabetic Nephropathy Key Players in Europe (2019-2020)
7.3 Europe Diabetic Nephropathy Market Size by Type (2015-2020)
7.4 Europe Diabetic Nephropathy Market Size by Application (2015-2020)
8 China
8.1 China Diabetic Nephropathy Market Size (2015-2020)
8.2 Diabetic Nephropathy Key Players in China (2019-2020)
8.3 China Diabetic Nephropathy Market Size by Type (2015-2020)
8.4 China Diabetic Nephropathy Market Size by Application (2015-2020)
9 Japan
9.1 Japan Diabetic Nephropathy Market Size (2015-2020)
9.2 Diabetic Nephropathy Key Players in Japan (2019-2020)
9.3 Japan Diabetic Nephropathy Market Size by Type (2015-2020)
9.4 Japan Diabetic Nephropathy Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Diabetic Nephropathy Market Size (2015-2020)
10.2 Diabetic Nephropathy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Diabetic Nephropathy Market Size by Type (2015-2020)
10.4 Southeast Asia Diabetic Nephropathy Market Size by Application (2015-2020)
11 India
11.1 India Diabetic Nephropathy Market Size (2015-2020)
11.2 Diabetic Nephropathy Key Players in India (2019-2020)
11.3 India Diabetic Nephropathy Market Size by Type (2015-2020)
11.4 India Diabetic Nephropathy Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Diabetic Nephropathy Market Size (2015-2020)
12.2 Diabetic Nephropathy Key Players in Central & South America (2019-2020)
12.3 Central & South America Diabetic Nephropathy Market Size by Type (2015-2020)
12.4 Central & South America Diabetic Nephropathy Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Diabetic Nephropathy Introduction
13.1.4 Novartis Revenue in Diabetic Nephropathy Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Diabetic Nephropathy Introduction
13.2.4 Merck Revenue in Diabetic Nephropathy Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Diabetic Nephropathy Introduction
13.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Abbott Laboratories
13.4.1 Abbott Laboratories Company Details
13.4.2 Abbott Laboratories Business Overview
13.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
13.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2015-2020)
13.4.5 Abbott Laboratories Recent Development
13.5 Sanofi
13.5.1 Sanofi Company Details
13.5.2 Sanofi Business Overview
13.5.3 Sanofi Diabetic Nephropathy Introduction
13.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2015-2020)
13.5.5 Sanofi Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Diabetic Nephropathy Introduction
13.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 AbbVie
13.7.1 AbbVie Company Details
13.7.2 AbbVie Business Overview
13.7.3 AbbVie Diabetic Nephropathy Introduction
13.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2015-2020)
13.7.5 AbbVie Recent Development
13.8 Reata Pharmaceuticals
13.8.1 Reata Pharmaceuticals Company Details
13.8.2 Reata Pharmaceuticals Business Overview
13.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
13.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2015-2020)
13.8.5 Reata Pharmaceuticals Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview
13.9.3 Bayer Diabetic Nephropathy Introduction
13.9.4 Bayer Revenue in Diabetic Nephropathy Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 Mitsubishi Tanabe Pharma
13.10.1 Mitsubishi Tanabe Pharma Company Details
13.10.2 Mitsubishi Tanabe Pharma Business Overview
13.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
13.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2015-2020)
13.10.5 Mitsubishi Tanabe Pharma Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Diabetic Nephropathy Key Market Segments
Table 2. Key Players Covered: Ranking by Diabetic Nephropathy Revenue
Table 3. Ranking of Global Top Diabetic Nephropathy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Diabetic Nephropathy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ACE Inhibitors
Table 6. Key Players of ARBs
Table 7. Key Players of Diuretics
Table 8. Key Players of Calcium Channel Blockers(CCBs)
Table 9. Key Players of Renin Inhibitors
Table 10. Key Players of Connective Tissue Growth Factor (CTGF) Inhibitors
Table 11. Key Players of Antioxidant Inflammation Modulators(AIMs)
Table 12. Key Players of Monocyte Chemoattractant Protein (MCP)Inhibitors
Table 13. Key Players of Endothelin-A Receptor(ETAR)Antagonist
Table 14. Key Players of G Protein-Coupled Receptors (GPCRs)
Table 15. Global Diabetic Nephropathy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Diabetic Nephropathy Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Diabetic Nephropathy Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Diabetic Nephropathy Market Share by Regions (2015-2020)
Table 19. Global Diabetic Nephropathy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Diabetic Nephropathy Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Diabetic Nephropathy Market Growth Strategy
Table 25. Main Points Interviewed from Key Diabetic Nephropathy Players
Table 26. Global Diabetic Nephropathy Revenue by Players (2015-2020) (Million US$)
Table 27. Global Diabetic Nephropathy Market Share by Players (2015-2020)
Table 28. Global Top Diabetic Nephropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Nephropathy as of 2019)
Table 29. Global Diabetic Nephropathy by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Diabetic Nephropathy Product Solution and Service
Table 32. Date of Enter into Diabetic Nephropathy Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 35. Global Diabetic Nephropathy Market Size Share by Type (2015-2020)
Table 36. Global Diabetic Nephropathy Revenue Market Share by Type (2021-2026)
Table 37. Global Diabetic Nephropathy Market Size Share by Application (2015-2020)
Table 38. Global Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 39. Global Diabetic Nephropathy Market Size Share by Application (2021-2026)
Table 40. North America Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 42. North America Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 43. North America Diabetic Nephropathy Market Share by Type (2015-2020)
Table 44. North America Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 45. North America Diabetic Nephropathy Market Share by Application (2015-2020)
Table 46. Europe Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 48. Europe Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Diabetic Nephropathy Market Share by Type (2015-2020)
Table 50. Europe Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Diabetic Nephropathy Market Share by Application (2015-2020)
Table 52. China Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 53. China Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 54. China Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 55. China Diabetic Nephropathy Market Share by Type (2015-2020)
Table 56. China Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 57. China Diabetic Nephropathy Market Share by Application (2015-2020)
Table 58. Japan Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 60. Japan Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Diabetic Nephropathy Market Share by Type (2015-2020)
Table 62. Japan Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Diabetic Nephropathy Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 66. Southeast Asia Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Diabetic Nephropathy Market Share by Type (2015-2020)
Table 68. Southeast Asia Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Diabetic Nephropathy Market Share by Application (2015-2020)
Table 70. India Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 71. India Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 72. India Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 73. India Diabetic Nephropathy Market Share by Type (2015-2020)
Table 74. India Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 75. India Diabetic Nephropathy Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Diabetic Nephropathy Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Diabetic Nephropathy Market Share (2019-2020)
Table 78. Central & South America Diabetic Nephropathy Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Diabetic Nephropathy Market Share by Type (2015-2020)
Table 80. Central & South America Diabetic Nephropathy Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Diabetic Nephropathy Market Share by Application (2015-2020)
Table 82. Novartis Company Details
Table 83. Novartis Business Overview
Table 84. Novartis Product
Table 85. Novartis Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 86. Novartis Recent Development
Table 87. Merck Company Details
Table 88. Merck Business Overview
Table 89. Merck Product
Table 90. Merck Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 91. Merck Recent Development
Table 92. Pfizer Company Details
Table 93. Pfizer Business Overview
Table 94. Pfizer Product
Table 95. Pfizer Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 96. Pfizer Recent Development
Table 97. Abbott Laboratories Company Details
Table 98. Abbott Laboratories Business Overview
Table 99. Abbott Laboratories Product
Table 100. Abbott Laboratories Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 101. Abbott Laboratories Recent Development
Table 102. Sanofi Company Details
Table 103. Sanofi Business Overview
Table 104. Sanofi Product
Table 105. Sanofi Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 106. Sanofi Recent Development
Table 107. Eli Lilly Company Details
Table 108. Eli Lilly Business Overview
Table 109. Eli Lilly Product
Table 110. Eli Lilly Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 111. Eli Lilly Recent Development
Table 112. AbbVie Company Details
Table 113. AbbVie Business Overview
Table 114. AbbVie Product
Table 115. AbbVie Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 116. AbbVie Recent Development
Table 117. Reata Pharmaceuticals Business Overview
Table 118. Reata Pharmaceuticals Product
Table 119. Reata Pharmaceuticals Company Details
Table 120. Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 121. Reata Pharmaceuticals Recent Development
Table 122. Bayer Company Details
Table 123. Bayer Business Overview
Table 124. Bayer Product
Table 125. Bayer Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 126. Bayer Recent Development
Table 127. Mitsubishi Tanabe Pharma Company Details
Table 128. Mitsubishi Tanabe Pharma Business Overview
Table 129. Mitsubishi Tanabe Pharma Product
Table 130. Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2015-2020) (Million US$)
Table 131. Mitsubishi Tanabe Pharma Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Nephropathy Market Share by Type: 2020 VS 2026
Figure 2. ACE Inhibitors Features
Figure 3. ARBs Features
Figure 4. Diuretics Features
Figure 5. Calcium Channel Blockers(CCBs) Features
Figure 6. Renin Inhibitors Features
Figure 7. Connective Tissue Growth Factor (CTGF) Inhibitors Features
Figure 8. Antioxidant Inflammation Modulators(AIMs) Features
Figure 9. Monocyte Chemoattractant Protein (MCP)Inhibitors Features
Figure 10. Endothelin-A Receptor(ETAR)Antagonist Features
Figure 11. G Protein-Coupled Receptors (GPCRs) Features
Figure 12. Global Diabetic Nephropathy Market Share by Application: 2020 VS 2026
Figure 13. Hospitals Case Studies
Figure 14. Cancer Research Institutes Case Studies
Figure 15. Diagnostic Labs Case Studies
Figure 16. Diabetic Nephropathy Report Years Considered
Figure 17. Global Diabetic Nephropathy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 18. Global Diabetic Nephropathy Market Share by Regions: 2020 VS 2026
Figure 19. Global Diabetic Nephropathy Market Share by Regions (2021-2026)
Figure 20. Porter's Five Forces Analysis
Figure 21. Global Diabetic Nephropathy Market Share by Players in 2019
Figure 22. Global Top Diabetic Nephropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Nephropathy as of 2019
Figure 23. The Top 10 and 5 Players Market Share by Diabetic Nephropathy Revenue in 2019
Figure 24. North America Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Europe Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. China Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Japan Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Southeast Asia Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. India Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Central & South America Diabetic Nephropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Bottom-up and Top-down Approaches for This Report
Figure 32. Data Triangulation
Figure 33. Key Executives Interviewed
TNF阻害剤の世界市場（～2026年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…- 腫瘍壊死因子α阻害剤の世界市場（～2026年） The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), i…
- 腫瘍壊死因子阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Market The global Tumor Necrosis Factor Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Necrosis Factor Inhibitors Scope and Market…
- シグナル伝達阻害剤の世界市場（～2026年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
- DPP IV阻害剤（DPP-4阻害剤）の世界市場（～2026年） DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of in…